Presently, several small molecule protein degraders are being evaluated for the treatment of a wide variety of disease indications; PROTACs is the most prominent sub-class in this segment with 8+ enabling technologies, claims Roots Analysis

Small-molecule-induced protein degradation has been demonstrated to possess the potential to drug a broader range of proteinaceous biological targets. It involves the selective recruitment of the body’s inherent protein degradation pathways, to eliminate disease causing / associated proteins, using bifunctional small molecule drugs. Presently, the most popular and promising class of interventions in this field of research, is proteolysis targeting chimeras (PROTACs); these can simultaneously bind a target protein and an E3-ubiquitin ligase, and thereby, facilitate the selective ubiquitination and eventual proteasome-mediated degradation of the target protein. The most interesting feature of this mechanism of drug action is the fact that PROTACs and other targeted protein degraders can eliminate protein targets regardless of their function.


To order this 330+ page report, which features 115+ figures and 180+ tables, please visit this link


The USD 3.3 billion (by 2030) financial opportunity within the targeted protein degradation enabling technologies market has been analyzed across the following segments:

  • Type of Payment
  • Upfront Payment
  • Milestone Payment


  • Types of Protein Degraders
  • Degronimids
  • SARDs / SERDs
  • Specific BET and DUB Inhibitors
  • Other Inhibitors


  • Therapeutic Areas
  • Oncological Disorders
  • Neurological Disorders
  • Others


  • Route of Administration
  • Oral
  • Intravenous
  • Others


  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific


The Targeted Protein Degradation Market, 2021-2030 report features the following companies, which we identified to be key players in this domain:

  • Arvinas
  • AstraZeneca
  • BioTheryX
  • C4 Therapeutics
  • Captor Therapeutics
  • Celgene
  • Genentech
  • Hinova Pharmaceuticals
  • Kangpu Biopharmaceuticals
  • Kymera Therapeutics
  • Mission Therapeutics
  • Progenra
  • Radius Health
  • Sanofi Genzyme
  • Zenopharm


Table of Contents


  1. Preface

    2. Executive Summary

  2. Introduction
  3. Current Market Landscape: Target Protein Degradation-Based Therapeutics
  4. Current Market Landscape: Target Protein Degradation Enabling Technologies
  5. Company Profiles
  6. Clinical Trial Analysis
  7. Academic Grants Analysis
  8. Publication Analysis


  1. Patent Analysis
  2. KOL Analysis
  3. Partnerships and Collaborations
  4. Funding and Investment Analysis
  5. Market Sizing and Opportunity Analysis


  1. Licensing Deal Structure


  1. Executive Insights


  1. Concluding Remarks


  1. Appendix 1: Tabulated Data


  1. Appendix 2: List of Companies and Organizations


To purchase a copy, please visit


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415